Evidence map›Paper›PMID 36643625›Full record

ArticlePeerJ2023

Comprehensive analysis of fatty acid metabolism-related gene signatures for predicting prognosis in patients with prostate cancer.

Hongbo Wang, Zhendong Liu, Yubo Wang, Dali Han, Yuelin Du, Bin Zhang, Yang He, Junyao Liu, Wei Xiong, Xingxing Zhang and 2 more

Open access · goldAbstract read
In one paragraph

Article in PeerJ, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Hongbo Wang *Lanzhou University Second Hospital, Lanzhou, Gansu, China.
Zhendong Liu *Department of Orthopaedic People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, Henan, China.
Yubo WangSchool of Basic Medicine and Forensic Medicine, Henan University of Science & Technology, Luoyang, Henan, China.
Dali HanLanzhou University Second Hospital, Lanzhou, Gansu, China.
Yuelin DuLanzhou University Second Hospital, Lanzhou, Gansu, China.
Bin ZhangLanzhou University Second Hospital, Lanzhou, Gansu, China.
Yang HeLanzhou University Second Hospital, Lanzhou, Gansu, China.
Junyao LiuLanzhou University Second Hospital, Lanzhou, Gansu, China.
Wei XiongLanzhou University Second Hospital, Lanzhou, Gansu, China.
Xingxing ZhangLanzhou University Second Hospital, Lanzhou, Gansu, China.
Yanzheng GaoDepartment of Orthopaedic People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, Henan, China.
Panfeng ShangLanzhou University Second Hospital, Lanzhou, Gansu, China.
Lanzhou University Second Hospital · CNLanzhou University · CNHenan Provincial People's Hospital · CNHenan University of Science and Technology · CNZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fatty acid metabolism (FAM) is an important factor in tumorigenesis and development. However, whether fatty acid metabolism (FAM)-related genes are associated with prostate cancer (PCa) prognosis is not known. Therefore, we established a novel prognostic model based on FAM-related genes to predict biochemical recurrence in PCa patients. First, PCa sequencing data were acquired from TCGA as the training cohort and GSE21032 as the validation cohort. Second, a prostate cancer prognostic model containing 10 FAM-related genes was constructed using univariate Cox and LASSO. Principal component analysis and t-distributed stochastic neighbour embedding analysis showed that the model was highly effective. Third, PCa patients were divided into high- and low-risk groups according to the model risk score. Survival analysis, ROC curve analysis, and independent prognostic analysis showed that the high-risk group had short recurrence-free survival (RFS), and the risk score was an independent diagnostic factor with diagnostic value in PCa patients. External validation using GSE21032 also showed that the prognostic model had high reliability. A nomogram based on a prognostic model was constructed for clinical use. Fourth, tumor immune correlation analyses, such as the ESTIMATE, CIBERSORT algorithm, and ssGSEA, showed that the high-risk group had higher immune cell infiltration, lower tumour purity, and worse RFS. Various immune checkpoints were expressed at higher levels in high-risk patients. In summary, this prognostic model is a promising prognostic biomarker for PCa that should improve the prognosis of PCa patients. These data provide new ideas for antitumour immunotherapy and have good potential value for the development of targeted drugs.

Indexed as

Prostatic NeoplasmsFatty AcidsHumansMaleNomogramsPrognosisReproducibility of ResultsFatty AcidsFatty acid metabolismImmune infiltrationPrognostic modelProstate cancerRecurrence free survival

Identifiers

PMID36643625
PMCPMC9838212
OpenAlexW4315486260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.